A carnivore diet is a restrictive diet that only includes meat, fish, and other animal products like dairy and eggs. More recently, it has been brought into the limelight by influencers and social media personalities. In fact, there is a whole community of "meatfluencer" who are sharing their meat-eating plans. One of them is Dr Paul Saladino MD, whose belief that there was no better way to prevent chronic diseases than a carnivore diet prompted him to write books and post videos regarding the same. He believed so much in this eating plan that he became a go-to person for many following the same plan, until recently, when he decided to quit.

Here Are Seven Reasons Why He Decided To Quit

Carnivore Diet Disrupted His Sleep

Switching to an all-meat diet isn't always straightforward, especially when it comes to digestion—a lesson Dr Saladino learned firsthand. He experienced sleep disturbances, likely due to the difficulty of digesting high-protein meals. Since protein takes longer to break down, it demands more energy from the body, which can interfere with rest.

According to Johns Hopkins Medicine, digestion slows by up to 50% during sleep. Additionally, many types of meat contain tyramine, a compound derived from the amino acid tyrosine. Increased tyramine intake can lead to health issues and also triggers the release of norepinephrine, a hormone that raises heart rate and blood pressure, making restful sleep harder to achieve.

He also experienced hypnagogic jerks—sudden muscle spasms that jolt the body awake. "I would fall asleep but then jerk myself awake like I was falling multiple times. It was stressful and traumatic, leading to poor sleep," he shared in his YouTube video.

Eating Only Meat May Have Triggered Heart Palpitations

Another concerning side effect Dr Saladino experienced was heart palpitations—episodes where his heart felt like it was racing or fluttering. While stress is a common cause, few would immediately link palpitations to meat consumption.

However, a sudden shift to an all-meat diet can lead to electrolyte imbalances. The elimination of carbohydrates lowers insulin levels, prompting the kidneys to excrete more sodium. This disrupts the balance of essential minerals like potassium and magnesium, which are crucial for heart function.

Muscle Cramps Became Persistent

Dr Saladino also suffered from frequent muscle cramps while following the carnivore diet. In a post on X, he emphasized the importance of maintaining adequate magnesium, calcium, and potassium levels to prevent cramping. He initially believed that animal-based foods provided sufficient minerals, but his ongoing cramps led him to reconsider.

"I started to think maybe long-term ketosis is not great for me,” he admitted on the *More Plates More Dates* podcast. “Probably not a great thing for most humans."

His Testosterone Levels Dropped Significantly

Dr Saladino also saw a decline in his testosterone levels after following the carnivore diet for over a year. "At the beginning of my carnivore experiment, my testosterone was about 800. After a year to a year and a half, it had dropped to around 500," he revealed.

The issue likely stems from excessive protein intake, which can elevate inflammation and disrupt hormone levels. A 2022 study published in Nutrition and Health found that consuming more than 35% of daily calories from protein can lead to various negative effects, including reduced testosterone.

He Had Chronically Low Insulin Levels

Because he largely eliminated carbohydrates—except for a small amount of fruit—Dr Saladino developed persistently low blood sugar. In his YouTube video, he explained, "I had very low insulin because I wasn’t eating carbohydrates, and the protein I consumed wasn’t insulinogenic enough."

While some diabetics report improved blood sugar control on the carnivore diet, its effects vary based on individual metabolic responses. For non-diabetics, low insulin can lead to hypoglycemia, causing symptoms like dizziness, confusion, a racing heart, and, in extreme cases, seizures or coma. Mild cases can be managed with fast-acting carbohydrates like juice or candy, but severe episodes require medical attention.

His Blood Test Results Showed Concerning Imbalances

Lab tests revealed that his magnesium levels were low, while his sex hormone-binding globulin (SHBG) was elevated—both potential red flags for long-term health issues.

A magnesium deficiency can cause numbness, tingling, fatigue, nausea, headaches, and muscle cramps. Since cramps often strike at night, low magnesium may also contribute to sleep disturbances.

High SHBG levels indicate an excess of circulating protein in the blood, which can increase the risk of heart disease, osteoporosis, and depression. To counteract these imbalances, introducing more magnesium-rich foods—such as leafy greens, nuts, beans, and yogurt—could be beneficial.

He Felt Cold All The Time

Electrolyte imbalances and metabolic disruptions can even affect body temperature, which Dr. Saladino experienced firsthand. "I was always cold,"he shared in his YouTube video.

Upon testing his thyroid function, he discovered that his total T3 and free T3 hormone levels were "not ideal." These hormones regulate metabolism, and low levels can slow down metabolic processes, leading to cold intolerance.

Beyond weight loss and diabetes control, GLP-1 drugs may offer mental health benefits by reducing the need for psychiatric hospital care among people with schizophrenia and type 2 diabetes (T2D), according to a new study published in The Lancet Psychiatry.

The findings showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and emergency department visits among people with both conditions.

What Did the Study Find?

Also read: Exclusive: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor

Researchers from Deakin University and the University of Queensland in Australia analyzed US health records of more than 70,000 adults with schizophrenia and T2D who received treatment between January 2018 and October 2026.

The researchers found that people taking GLP-1 drugs were:

• 24% less likely to require psychiatric hospitalization than those not taking any of the compared diabetes medications.
• 18% less likely to require psychiatric hospitalization than those taking DPP-4 inhibitors.
• 17% less likely to require psychiatric hospitalization than those taking SGLT2 inhibitors.

GLP-1 use was also associated with fewer psychiatric emergency department visits. Compared with the same groups, users were:

• 29% less likely to require emergency care than those not taking any of the compared diabetes medications.
• 13% less likely than those taking DPP-4 inhibitors.
• 20% less likely than those taking SGLT2 inhibitors.

Further, when the researchers analyzed individual drugs, the association was observed with semaglutide, liraglutide, and tirzepatide, but not dulaglutide.

GLP-1 Drugs Not Primary Treatment for Schizophrenia

Read More: Ozempic Baby: Can GLP-1 Drugs Help Women With PMOS Conceive?

The researchers cautioned that the observational study cannot establish that GLP-1 drugs directly reduce the need for acute psychiatric care.

They said the medications should not be considered primary psychiatric treatments or prescribed solely to reduce psychiatric hospitalizations and emergency visits.

Instead, the findings point to a potential additional benefit when GLP-1 drugs are prescribed for appropriate metabolic indications as part of integrated cardiometabolic and mental health care.

“The findings suggest that lower psychiatric acute-care use could be a favourable secondary benefit when GLP-1-based therapies are clinically indicated for metabolic management,” the researchers said.

They added that randomized clinical trials and mechanistic studies are needed to determine whether the drugs have a direct effect on psychiatric outcomes. Further research should also investigate their potential benefits in people with schizophrenia who do not have T2D.

Why Is Type 2 Diabetes More Common in People With Schizophrenia?

Schizophrenia is a serious psychiatric disorder associated with disability, other health conditions, and premature mortality. Cardiometabolic diseases, including T2D, contribute substantially to this burden.

Studies suggest that diabetes may be up to five times more common among people with schizophrenia than among those without the condition. Approximately one in five people with schizophrenia may also have diabetes.

Several factors may contribute to this increased risk, including:

• Obesity
• High cholesterol and other abnormal blood lipid levels
• Elevated blood sugar
• Smoking
• Unhealthy diet
• Physical inactivity
• Poor sleep
• Stress

Could GLP-1 Drugs Help Address Both Conditions?

GLP-1 receptor agonists are an established class of medications used to manage T2D and, in some cases, obesity. Their potential role in people with schizophrenia is of growing interest because of the high burden of metabolic disease in this population.

However, whether these medications directly improve psychiatric outcomes remains uncertain.

The latest findings suggest that GLP-1 treatment may be associated with reduced use of acute psychiatric care among people with schizophrenia and T2D. Further clinical trials are needed before any direct mental health benefit can be established.

Originally developed to treat type 2 diabetes and obesity, GLP-1 receptor agonists have shown benefits beyond blood sugar control and weight loss, including for cardiovascular and kidney health.

Some women, particularly those with polyendocrine metabolic ovarian syndrome (PMOS), formerly known

as PCOS, have reported conceiving after taking these medications.

Although GLP-1 drugs can support weight loss and improve metabolic health, evidence that they directly improve fertility remains limited.

Woman Says GLP-1 Drug Helped Her Conceive

For 30-year-old Ashlee Amborn, pregnancy was challenging. According to ABC News, she had PMOS, one functioning fallopian tube and half a uterus, which complicated her chances of conceiving naturally.

After years of fertility treatments, she conceived her first two children. Four months after her second child's birth, she became pregnant again.

Amborn said a GLP-1 drug prescribed to manage her PMOS symptoms, including inflammation and hormonal imbalances, helped her conceive. She became pregnant after taking the medication for a month.

"It was kind of these mixed emotions of, 'Holy cow, I'm pregnant,'" Amborn said. "I did this on my own without fertility treatment. All it took was a GLP-1."

Also read: Sorority Rush Sees Ozempic Trend: What Young Women Should Know Before Using GLP-1 Drugs

What Does Research Say?

A recent review published in the Journal of the Brazilian Reproduction Association (JBRA) Assisted Reproduction suggests a possible association between GLP-1 use and improved fertility outcomes in women with obesity and PMOS, particularly those also taking metformin, a medication used to manage blood sugar.

Weight loss and improved insulin sensitivity may support ovulation and reduce ovarian dysfunction. However, more research is needed to establish whether these medications improve pregnancy or live-birth rates.

Can GLP-1 Drugs Affect Ovulation?

Dr. Jacinta Anyaoku, a physician at Maven Clinic specializing in obesity and women's health in midlife, told ABC News that research has not established a direct link between GLP-1 use and ovulation rates, although she has observed potential benefits among her patients.

"When you lose weight, your inflammation goes down," Anyaoku said. "It actually can help with improving your rate of ovulation. Your egg quality could potentially improve if you have reduced inflammation, and so these are all potential effects that come with GLP-1 use."

Sharrón L. Manuel, a board-certified OB/GYN and reproductive endocrinology specialist at HRC Fertility, attributes the reported "Ozempic Baby Boom" largely to weight loss and improved metabolic health, which may help restore ovulation.

Excess body weight can disrupt the hypothalamic-pituitary-ovarian (HPO) axis, contribute to insulin resistance and affect egg and uterine lining quality.

Manuel also points to preliminary research suggesting GLP-1 drugs may influence reproductive function through hormonal regulation, reduced inflammation and improved insulin sensitivity. However, preclinical findings involving ovarian function and endometrial receptivity require further investigation in humans.

Read More: GLP-1 Drugs Ozempic, Zepbound Use Rises 24-Fold Among American Women After Childbirth

Can GLP-1 Drugs Be Used During Pregnancy?

GLP-1 drugs should not be used during pregnancy. Women planning to conceive should consult their healthcare professional about stopping treatment. For semaglutide, prescribing guidance recommends discontinuation at least two months before a planned pregnancy.

Women should also seek medical advice about using these medications while breastfeeding.

The American College of Obstetricians and Gynecologists advises against weight-loss medications during pregnancy. Women considering GLP-1 treatment should discuss the risks, benefits and timing with their healthcare professional, particularly if they plan to conceive.

What About Birth Control?

Tirzepatide, sold under the brand names Mounjaro and Zepbound, can affect oral contraceptive absorption. Its prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting treatment and for four weeks after each dose increase.

Parkinson’s disease (PD) symptoms differ between women and men, a new study has found, with potential implications for treatment.

Presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul, the study found that women experienced more severe motor complications and depression. Men, however, had greater cognitive impairment.

“Sex differences in movement disorders remain understudied and undervalued despite having an important impact on clinical outcomes in both real-life and clinical trial settings,” said Dr. Marina Picillo, assistant professor of neurology at AOU San Giovanni di Dio e Ruggi d’Aragona.

What Did The Study Find?

Researchers retrospectively analyzed 10 years of clinical data from more than 10,000 Parkinson’s patients examined at a movement disorders clinic in Germany.

The findings showed that women had a greater burden of motor complications and depression. Men were more likely to experience cognitive impairment, REM sleep behavior disorder (RBD) and loss of smell.

“By analyzing data for more than 10,000 PD patients, this study confirmed that depression is more common in women, while RBD, worse cognition, and poorer olfaction are more prevalent in men,” Picillo said. “With good representation of women (40%), it also confirmed a greater female burden of motor complications.”

How Could The Findings Help?

The findings highlight the need to account for sex differences in Parkinson’s disease management and clinical trial design, particularly given the historical underrepresentation of women in neurological research. However, the factors underlying these differences remain unclear.

Picillo stressed that considering sex differences when tailoring treatment and designing clinical trials could be an important first step toward precision medicine in Parkinson’s disease.

“This would be the very first, basic step for boosting precision medicine in PD,” she said.

What Is Parkinson’s Disease?

Parkinson’s disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing nerve cells in the brain.

Common symptoms include tremors, muscle stiffness, slowed movement and impaired balance. As the disease progresses, patients may have difficulty walking, speaking and performing everyday tasks.

The condition can also cause cognitive impairment, depression, anxiety, sleep disturbances, pain and swallowing difficulties, affecting patients’ independence and quality of life. Although it primarily affects older adults, younger people can also develop Parkinson’s disease.

Global Burden Of Parkinson’s Disease

Parkinson’s disease affected an estimated 11.9 million people worldwide in 2021. The number is projected to reach 25.2 million by 2050, a 112% increase.

Can Parkinson’s Disease Be Prevented?

There is currently no established way to prevent Parkinson’s disease. However, research suggests that certain lifestyle and environmental factors may influence disease risk.

• Physical activity: Regular exercise supports overall health, although its role in preventing Parkinson’s disease remains under investigation.
• Diet and nutrition: A balanced diet supports brain health, but no specific diet has been proven to prevent the disease.
• Environmental factors: Exposure to certain pesticides and other environmental pollutants has been associated with Parkinson’s disease risk. Reducing harmful exposures may help address potential risk factors.